Alto Neuroscience (ANRO) Operating Leases (2024 - 2026)

Alto Neuroscience (ANRO) has 3 years of Operating Leases data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 19.41% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 19.41% YoY), and the FY2025 full-year result was $3.8 million, down 15.35% from the prior year.
• Operating Leases eased to $3.6 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.2 million in Q3 2024 to a low of $3.6 million in Q1 2026.
• A 3-year average of $4.2 million and a median of $4.2 million in 2025 frame the typical range for Operating Leases.
• Peak annual rise in Operating Leases reached 15.35% in 2025, while the deepest fall reached 23.73% in 2025.
• Tracing ANRO's Operating Leases over 3 years: stood at $4.5 million in 2024, then fell by 15.35% to $3.8 million in 2025, then decreased by 7.01% to $3.6 million in 2026.
• Business Quant data shows ANRO's Operating Leases at $3.6 million in Q1 2026, $3.8 million in Q4 2025, and $4.0 million in Q3 2025.